Trial reportBMC oral health2026
Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial.
Trial report in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04364555 (Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral lichen planus (OLP) is a chronic immune‑mediated inflammatory disorder affecting the oral mucosa and characterized by recurring exacerbations and remissions. Complete healing is uncommon. Currently, there is no established curative therapy for OLP. Management strategies are aimed at alleviating clinical symptoms by reducing the underlying inflammatory response. Although some effect of topical corticosteroids has been reported, the level of evidence remains low, as few studies are randomized and placebo controlled. This study evaluated the efficacy of clobetasol compared with placebo in the treatment of symptomatic OLP and sought to determine whether once-daily is as effective as twice-daily administration.
methodsPatients with symptomatic OLP were randomly allocated to three treatment groups: clobetasol propionate 0.025% oral gel twice daily (Active 2, n = 22), clobetasol propionate 0.025% oral gel once daily and placebo oral gel once daily (Active 1, n = 26) and placebo oral gel twice daily (Placebo, n = 25). All three groups were instructed to rinse with the assigned oral gel for 1 min twice daily for 4 weeks. The primary outcome was the Oral Disease Severity Score (ODSS). Secondary outcomes were the visual analogue scale (VAS) score for pain, the VAS score for burning sensation, the Oral Health Impact Profile (OHIP-14), and the Global Rating of Change (GRC).
resultsIn both intervention groups (Active 2 and 1), improvement in the ODSS (p < 0.05) and the GRC (p < 0.05) after 4 weeks was significant compared with control group (Placebo). No significant differences were observed between the intervention groups in ODSS and GRC. Nor were any significant differences in the pain score, the burning sensation score, or the OHIP-14 noted between the intervention groups and the control group. Adverse events were mild with no significant differences between the intervention groups and the control group. Despite receiving antifungal prophylaxis, 27% of the participants had oral candidiasis at the end of treatment.
conclusionsThe results suggest that topical clobetasol propionate 0.025% oral gel is more effective than placebo in improving disease severity (ODSS) and global change (GRC) in patients with symptomatic OLP. The results also suggest that once-daily treatment is as effective as twice-daily treatment.
trial registrationThis trial was registered at Clinical Trials.gov on April 20, 2020, under registration number NCT04364555.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.